Atrion Reports Results for Fourth Quarter and Full Year 2018
February 26 2019 - 4:30PM
Atrion Corporation (NASDAQ: ATRI) announced today that for the
fourth quarter of 2018 revenues were $34.9 million compared to
$34.0 million in the same period of 2017, net income was $7.7
million compared to $8.6 million in the prior-year period, and
diluted earnings per share were $4.17 compared to $4.66 in the
prior-year period. For the full year 2018 compared to 2017, Atrion
increased revenues to $152.4 million from $146.6 million, net
income was $34.3 million compared to $36.6 million, and diluted
earnings per share were $18.44 compared to $19.71.
David Battat, President & CEO, commenting on
the results for the fourth quarter and the full year 2018 as
compared to the prior-year periods, said, "We are pleased that our
revenues were up 3% in the quarter and 4% for the full year despite
the significant decline in Ophthalmic sales that was discussed in
prior press releases. Those sales were lower by 17% in the quarter
and 23% for the full year.” Mr. Battat continued, “Full year
comparisons of net income and diluted EPS are distorted because our
2018 tax rate was higher than the prior year due to significant,
non-recurring tax benefits in 2017.”
Mr. Battat continued, “Although operating income
showed a small year-over-year improvement, operating income for
2018 was 27% of sales, a testament to both the clinical demand for
our products and the efficiency of our operations. As a result,
cash flow from operations in 2018 funded an increase of $6.4
million in working capital, $17.5 million in manufacturing
investments and $9.4 million in dividend payments. In addition cash
and short and long term investments increased by $14.8 million
during the year, bringing the total as of December 31, 2018 to
$89.5 million.”
Commenting on the outlook for 2019, Mr. Battat
said, “We anticipate that Ophthalmic sales will stabilize in the
second quarter of this year, while other major product areas will
begin to benefit from new product releases. We are particularly
excited that, after a multi-year development process, the latest
generation of our flagship cardiovascular technology, the
Myocardial Protection System (MPS 3), is undergoing a limited
market release in Canada, and we hope to have FDA clearance for the
U.S. market this year. The MPS 3 is a significant step forward in
our cardiovascular portfolio, expanding the benefits of this
platform to both clinicians and patients. We are confident that our
MPS 3 will remain the market leading technology in its niche for
several years to come.”
Atrion Corporation develops and manufactures
products primarily for medical applications. The Company’s website
is www.atrioncorp.com.
Statements in this press release that are
forward looking are based upon current expectations and actual
results or future events may differ materially. Such
statements include, but are not limited to, Atrion’s expectations
regarding stabilizing Ophthalmic sales, benefits from new product
releases, FDA clearance of MPS 3 in the U.S. market, and MPS 3
market position. Words such as “expects,” “believes,”
“anticipates,” “intends,” "should", "plans," "will" and variations
of such words and similar expressions are intended to identify such
forward-looking statements. Forward-looking statements
involve risks and uncertainties. The following are some of
the factors that could cause actual results or future events to
differ materially from those expressed in or underlying our
forward-looking statements: changing economic, market and
business conditions; acts of war or terrorism; the effects of
governmental regulation; competition and new technologies;
slower-than-anticipated introduction of new products or
implementation of marketing strategies; the Company’s ability to
protect its intellectual property; changes in the prices of raw
materials; changes in product mix; and intellectual property and
product liability claims and product recalls. The foregoing
list of factors is not exclusive, and other factors are set forth
in the Company’s filings with the Securities and Exchange
Commission. The forward-looking statements in this press release
are made as of the date hereof, and we do not undertake any
obligation, and disclaim any duty, to supplement, update or revise
such statements, whether as a result of subsequent events, changed
expectations or otherwise, except as required by applicable
law.
Contact: |
|
Jeffery Strickland |
|
|
Vice President and Chief Financial Officer |
|
|
(972) 390-9800 |
ATRION CORPORATIONCONSOLIDATED
STATEMENTS OF INCOME(In thousands, except per
share data) |
|
|
Three Months Ended |
|
Twelve Months Ended |
|
December 31, |
|
December 31, |
|
2018(unaudited) |
|
2017(unaudited) |
|
|
2018 |
|
|
|
2017 |
|
Revenues |
$ |
34,926 |
|
|
$ |
34,024 |
|
$ |
152,448 |
|
|
$ |
146,595 |
|
Cost of goods
sold |
|
19,321 |
|
|
|
18,001 |
|
|
80,670 |
|
|
|
75,841 |
|
Gross profit |
|
15,605 |
|
|
|
16,023 |
|
|
71,778 |
|
|
|
70,754 |
|
Operating
expenses |
|
7,287 |
|
|
|
7,730 |
|
|
30,071 |
|
|
|
29,480 |
|
Operating income |
|
8,318 |
|
|
|
8,293 |
|
|
41,707 |
|
|
|
41,274 |
|
|
|
|
|
|
|
|
|
Interest and
dividend income |
|
389 |
|
|
|
259 |
|
|
1,562 |
|
|
|
1,065 |
|
Other investment
income (loss) |
|
(106 |
) |
|
|
-- |
|
|
(1,275 |
) |
|
|
-- |
|
Other
income |
|
22 |
|
|
|
-- |
|
|
42 |
|
|
|
1 |
|
Income before
income taxes |
|
8,623 |
|
|
|
8,552 |
|
|
42,036 |
|
|
|
42,340 |
|
Income tax benefit
(provision) |
|
(874 |
) |
|
|
94 |
|
|
(7,781 |
) |
|
|
(5,747 |
) |
Net
income |
$ |
7,749 |
|
|
$ |
8,646 |
|
$ |
34,255 |
|
|
$ |
36,593 |
|
|
|
|
|
|
|
|
|
Income per basic
share |
$ |
4.18 |
|
|
$ |
4.67 |
|
$ |
18.49 |
|
|
$ |
19.82 |
|
|
|
|
|
|
|
|
|
Weighted average
basic shares outstanding |
|
1,853 |
|
|
|
1,852 |
|
|
1,853 |
|
|
|
1,846 |
|
|
|
|
|
|
|
|
|
|
$ |
4.17 |
|
|
$ |
4.66 |
|
$ |
18.44 |
|
|
$ |
19.71 |
|
Income per diluted
share |
|
|
|
|
|
|
|
Weighted average
diluted shares outstanding |
|
1,860 |
|
|
|
1,857 |
|
|
1,858 |
|
|
|
1,857 |
|
ATRION CORPORATIONCONSOLIDATED
BALANCE SHEETS(In thousands) |
|
|
|
Dec. 31, |
|
|
Dec. 31, |
ASSETS |
|
2018 |
|
|
2017 |
|
|
|
|
Current assets: |
|
|
|
Cash and cash
equivalents |
$ |
58,753 |
|
$ |
30,136 |
Short-term
investments |
|
9,684 |
|
|
35,468 |
Total cash and short-term
investments |
|
68,437 |
|
|
65,604 |
Accounts
receivable |
|
17,014 |
|
|
17,076 |
Inventories |
|
33,572 |
|
|
29,354 |
Prepaid expenses and
other |
|
3,242 |
|
|
3,199 |
Total current
assets |
|
122,265 |
|
|
115,233 |
Long-term
investments |
|
21,048 |
|
|
9,136 |
Property, plant
and equipment, net |
|
74,893 |
|
|
66,369 |
Other assets |
|
13,010 |
|
|
13,042 |
|
|
|
|
|
$ |
231,216 |
|
$ |
203,780 |
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS’
EQUITY |
|
|
|
|
|
|
|
Current
liabilities |
|
10,220 |
|
|
9,622 |
Line of
credit |
|
-- |
|
|
-- |
Other non-current
liabilities |
|
10,229 |
|
|
9,770 |
Stockholders’
equity |
|
210,767 |
|
|
184,388 |
|
|
|
|
|
$ |
231,216 |
|
$ |
203,780 |
ATRION (NASDAQ:ATRI)
Historical Stock Chart
From Mar 2024 to Apr 2024
ATRION (NASDAQ:ATRI)
Historical Stock Chart
From Apr 2023 to Apr 2024